大博医疗(002901) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 reached ¥565,128,470.34, representing a 50.38% increase compared to ¥375,794,614.09 in the same period last year[3]. - Net profit attributable to shareholders was ¥101,631,978.19, a significant increase of 2,331.04% from ¥4,180,589.82 year-on-year[3]. - The net profit after deducting non-recurring gains and losses was ¥89,045,803.34, up 862.68% from a loss of ¥11,675,344.11 in the previous year[3]. - The basic earnings per share (EPS) was ¥0.2455, a 2,330.69% increase from ¥0.0101 in the same quarter last year[3]. - The weighted average return on equity (ROE) improved to 3.24%, up from 0.14% in the previous year[3]. - Total revenue for the period reached ¥1,529,257,676.10, representing a 35.88% increase compared to ¥1,125,437,608.63 in the same period last year[7]. - Net profit for Q3 2024 was CNY 263,149,336.98, up 124% from CNY 117,469,494.60 in the same period last year[21]. - The total comprehensive income for the period attributable to the parent company was CNY 238,882,775.29, significantly higher than CNY 97,997,431.75 in Q3 2023, reflecting a growth of approximately 143.5%[22]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was ¥208,812,403.51, a remarkable increase of 1,908.47% from ¥10,396,582.34 last year[3]. - The cash flow from operating activities showed a 165.97% increase in tax refunds received, amounting to ¥10,623,484.85 compared to ¥3,994,230.02[8]. - The total cash inflow from operating activities was CNY 1,737,849,496.04, compared to CNY 1,453,380,107.21 in the previous year, marking an increase of about 19.6%[23]. - The company's total current assets amounted to RMB 2,881,863,831.91, a decrease of 8.65% from RMB 3,155,364,707.34 at the beginning of the period[15]. - The company's cash and cash equivalents decreased to RMB 1,011,928,158.97 from RMB 1,227,869,040.94, reflecting a decline of 17.6%[15]. - Cash and cash equivalents at the end of Q3 2024 amounted to CNY 159,891,883.23, up from CNY 144,684,750.16 at the end of Q3 2023[25]. Liabilities and Equity - The total assets at the end of the reporting period were ¥4,639,740,860.70, a decrease of 3.86% from the previous year's end[3]. - The equity attributable to shareholders was ¥3,058,491,836.78, reflecting a 3.42% decrease compared to the previous year[3]. - The company reported a significant decrease in short-term loans, down 77.21% to ¥72,050,138.87 from ¥316,129,513.07, due to repayment of loans[7]. - Total liabilities decreased to CNY 1,202,442,910.82 from CNY 1,479,129,740.59, representing a reduction of approximately 19%[18]. - The total equity attributable to shareholders increased to CNY 3,163,190,723.47 from CNY 3,058,479,990.20, marking a growth of about 3%[19]. Operational Costs and Expenses - Operating costs increased to ¥482,102,549.84, up 30.91% from ¥368,265,693.97, primarily due to higher sales volume[7]. - Research and development expenses increased to CNY 214,640,411.75, compared to CNY 191,799,717.78 in Q3 2023, reflecting a growth of approximately 12%[20]. - The company reported a gross profit margin improvement, with total operating costs rising to CNY 1,262,754,773.03, compared to CNY 1,046,739,500.28 in the previous year[20]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,330, with no preferred shareholders[9]. - The top ten shareholders held a combined 86.54% of the company's shares, with the largest shareholder owning 43.46%[10]. - The company approved a stock option incentive plan on September 10, 2024, allowing for the grant of 7,131,600 stock options at an exercise price of RMB 23.89 per option[14]. - The company plans to repurchase shares with a total fund of no less than RMB 10 million and no more than RMB 20 million, with a maximum repurchase price of RMB 35.00 per share[14]. - As of October 30, 2024, the company had repurchased a total of 6,146,900 shares, accounting for 1.4847% of the total share capital, with a total transaction amount of RMB 192,845,889.03[14]. Future Plans and Market Strategy - The company plans to continue expanding its market presence and product offerings, focusing on medical device sales and international market development[7].